Intracellular apoptosis-inducing factor is induced by a vacuolar type H+-ATPase inhibitor in B lineage cells.
We previously reported that concanamycin A, a specific inhibitor of vacuolar type H+-ATPases, induces DNA fragmentation in B cell hybridoma HS-72 cells. In the present study, we found that the cytosol from concanamycin A-treated HS-72 cells had a cytotoxic effect on intact cells in a cell viability assay. While activin A also induced apoptosis in HS-72 cells, the cytosol from activin A-treated HS-72 cells had no effect on cell viability. We purified the cytosol from concanamycin A-treated HS-72 cells by a four-step procedure: ultracentrifugation; HiTrap heparin column chromatography; HiTrap Q column chromatography; and reverse-phase high performance liquid chromatography on a C18 hydrophobic support. The biologically active fraction, which was used as partially purified cytosol, gave a specific band of protein with a molecular mass of 33 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The mechanism of cell death was examined by observing changes in nuclear morphology, an increase in the proportion of fragmented DNA, and the typical ladder pattern of degraded chromosomal DNA, indicating the induction of apoptosis in cells cultured with the partially purified cytosol. The overexpression of human Bcl-2 suppressed apoptosis, indicating that the cytosol from concanamycin A-treated HS-72 cells induces apoptosis by a Bcl-2-inhibiting mechanism. These findings suggest that concanamycin A, a vacuolar type H+-ATPase inhibitor, produces intracellular apoptosis-inducing factor in B cell hybridoma.
Hashimoto
S
S
Division of Maxillofacial and Neck Reconstruction, Graduate School, Tokyo Medical and Dental University, Japan.
Ishisaki
A
A
Yamato
K
K
Aiko
K
K
Amagasa
T
T
Nishihara
T
T
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D051033:Apoptosis Inducing Factor; D001402:B-Lymphocytes / Q000378:metabolism*; D016923:Cell Death / Q000502:physiology; D002460:Cell Line / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D003208:Concanavalin A / Q000494:pharmacology; D003600:Cytosol / Q000737:chemistry / Q000502:physiology; D005420:Flavoproteins / Q000302:isolation & purification / Q000378:metabolism*; D006801:Humans; D007425:Intracellular Membranes / Q000378:metabolism*; D008565:Membrane Proteins / Q000302:isolation & purification / Q000378:metabolism*; D051379:Mice; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000502:physiology; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors*; D014617:Vacuoles / Q000201:enzymology*
C494829:AIFM1 protein, human; D051033:Apoptosis Inducing Factor; D005420:Flavoproteins; D008565:Membrane Proteins; C494830:AIFM1 protein, mouse; D019253:Proto-Oncogene Proteins c-bcl-2; D003208:Concanavalin A; D006180:Proton-Translocating ATPases